Evidence map›Paper›PMID 37426419›Full record

ArticleFrontiers in molecular biosciences2023

Pharmacological effects and mechanisms of YiYiFuZi powder in chronic heart disease revealed by metabolomics and network pharmacology.

Yuming Wang, Xue Li, Min Qi, Xiaokai Li, Fangfang Zhang, Yuyu Wang, Junke Wu, Lexin Shu, Simiao Fan, Yunfei Li and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in molecular biosciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Yuming WangSchool of Chinese Materia, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Xue LiSchool of Chinese Materia, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Min QiTIPRHUYA Advancing Innovative Medicines Ltd., Tianjin, China.
Xiaokai LiSchool of Chinese Materia, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Fangfang ZhangSchool of Chinese Materia, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Yuyu WangSchool of Chinese Materia, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Junke WuSchool of Chinese Materia, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Lexin ShuSchool of Chinese Materia, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Simiao FanSchool of Chinese Materia, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Yunfei LiSchool of Chinese Materia, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Yubo LiSchool of Chinese Materia, Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Tianjin University of Traditional Chinese Medicine · CNShanghai Innovative Research Center of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

biomarkerchronic heart diseasemetabolomicspathwaysYiYiFuZi powder

Identifiers

PMID37426419
PMCPMC10327484
OpenAlexW4381853269

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.